{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS",
    "query": {
      "condition": "SOLID TUMORS"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5449,
    "total_pages": 545,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T07:17:53.241Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02228811",
      "title": "A Study of DCC-2701 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Tumors",
        "Metastatic Solid Tumors",
        "Cancers With MET Genomic Alterations",
        "Cancers With TRK Genomic Alterations"
      ],
      "interventions": [
        {
          "name": "DCC-2701 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deciphera Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2014-06",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-01",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228811"
    },
    {
      "nct_id": "NCT01534598",
      "title": "FdCyd and THU for Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "FdCyd + THU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 59,
      "start_date": "2012-03-05",
      "completion_date": "2025-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01534598"
    },
    {
      "nct_id": "NCT05284214",
      "title": "Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab-containing therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Partner Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-01",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284214"
    },
    {
      "nct_id": "NCT04204434",
      "title": "Biomarkers For Immune Checkpoint Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Cancer",
        "Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2016-11-29",
      "completion_date": "2024-04-26",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04204434"
    },
    {
      "nct_id": "NCT00002504",
      "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous/Nonmalignant Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1992-08",
      "completion_date": "1999-02",
      "has_results": false,
      "last_update_posted_date": "2011-05-12",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 5,
      "location_summary": "Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002504"
    },
    {
      "nct_id": "NCT06730347",
      "title": "A Study of Lorigerlimab in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Clear Cell Adenocarcinoma of Ovary",
        "Clear Cell Adenocarcinoma of Vulva",
        "Clear Cell Adenocarcinoma of Vagina",
        "Clear Cell Adenocarcinoma of Cervix",
        "Clear Cell Adenocarcinoma of Uterus",
        "Clear Cell Adenocarcinoma of Fallopian Tube",
        "Clear Cell Adenocarcinoma of Peritoneum",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Lorigerlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2025-05-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Orleans, Louisiana • Grand Rapids, Michigan + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06730347"
    },
    {
      "nct_id": "NCT04788147",
      "title": "Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Cancer, Lung",
        "Cancer, Bone",
        "Metastasis to Lung",
        "Metastasis to Bone"
      ],
      "interventions": [
        {
          "name": "RMRS IDE Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "RefleXion Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-03-26",
      "completion_date": "2021-12-20",
      "has_results": true,
      "last_update_posted_date": "2023-10-31",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Dallas, Texas",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04788147"
    },
    {
      "nct_id": "NCT00546247",
      "title": "A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Epofolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2008-01",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546247"
    },
    {
      "nct_id": "NCT02354547",
      "title": "A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "SGT-53",
          "type": "GENETIC"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "SynerGene Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-12",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02354547"
    },
    {
      "nct_id": "NCT02527434",
      "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Bladder Cancer",
        "Triple-negative Breast Cancer",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Tremelimumab monotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4736 monotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI4736 + tremelimumab combination therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "150 Years",
        "sex": "ALL",
        "summary": "18 Years to 150 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-11-02",
      "completion_date": "2023-03-28",
      "has_results": true,
      "last_update_posted_date": "2023-11-15",
      "last_synced_at": "2026-10-14T07:17:53.241Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Memphis, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02527434"
    }
  ]
}